您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Sivelestat
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Sivelestat
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Sivelestat图片
CAS NO:127373-66-4
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)434.46
FormulaC20H22N2O7S
CAS No.127373-66-4 (free acid);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 86 mg/mL (197.9 mM)
Water: <1 mg/mL
Ethanol: 86 mg/mL (197.9 mM)
Solubility (In vivo)5% DMSO+40% PEG 300+5% Tween 80+ddH2O: 23mg/mL
SynonymsONO5046, LY544349, EI546; ONO 5046; ONO5046; ONO-5046; LY544349; LY-544349; LY 544349; EI 546 sodium salt hydrate, Elaspol sodium salt hydrate, LY 544349 sodium salt hydrate, Trade name: Elaspol.
实验参考方法
In Vitro

In vitro activity: Sivelestat suppresses both adhesion and transmigration of neutrophils to the endothelium


Kinase Assay: Sivelestat(ONO5046; LY544349; EI546) is a competitive inhibitor of human neutrophil elastase(IC50 = 44 nM; Ki=200 nM); also inhibited leukocyte elastase obtained from rabbit, rat, hamster and mouse.


Cell Assay: HUVEC are grown to confluence on fibronectin (25 μg/mL) coated Falcon cell culture inserts. Neutrophils stimulated by PAF (0.1 mM) are added to the HUVEC monolayers (upper chamber). The upper chamber is exposed to 2 mL of HUMEDIA and rehydrated at 37 ℃ for 1 h in the absence or the presence (50 μg/mL) of sivelestat. Subsequently, the upper chamber is removed and the fluid in the lower chamber is collected.

In VivoIntraoperative administration of sivelestat effectively reduced neutrophil induction and activation in the lung and improved oxygenation after cardiopulmonary bypass in a piglet model.By inhibiting neutrophil elastase, sivelestat has a direct action to the accumulated and activated leucocytes, offering efficient protection against the production of oxygen radicals and cytokines.
Animal modelNeonatal piglets
Formulation & DosageDissolved in 0.9% saline solution; 2 mg/kg/h; Intraoperative administration
ReferencesInteract Cardiovasc Thorac Surg. 2008 Oct;7(5):785-8; Dig Dis Sci. 2014 Apr;59(4):787-94; BJU Int. 2011 Jan;107(2):329-36.